Compare Enact Holdings Inc (ACT) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enact Holdings Inc vs Biogen Inc — how do they compare? Enact Holdings Inc trades at $49.93 (market cap $6.75B), while Biogen Inc trades at $204 (market cap $30.13B). The key difference: Biogen Inc is far larger — about 4.5× Enact Holdings Inc's market cap, and Enact Holdings Inc pays a 1.95% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| ACT | BIIB | |
|---|---|---|
Market Cap | $6.75B | $30.13B |
Sector | Technology | Health |
52-Week High | $49.12 | $216.63 |
52-Week Low | $34.93 | $128.93 |
Enterprise Value | $7.05B | $37.20B |
Dividend Yield | 1.95% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
